SCHEMBL4865232

SCHEMBL4865232

COc1ccc(N(NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
ESR2 Q92731 1/20 0.47
NOX1 Q9Y5S8 1/20 0.47
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CACNA1B Q00975 2/20 0.39
MAOB P27338 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.38
SLC2A1 P11166 1/20 0.38
CTSL P07711 1/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10564385 0.88 KDM4E (0.42) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL14153907 0.87 MAPT (0.41) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL28420950 0.85 MIF (0.46) MAPTNPC1RAB9APOLBCTSL
SCHEMBL14108128 0.85 EPHX2 (0.41) MAPTSMN1; SMN2TP53POLBKMT2A
SCHEMBL10565579 0.83 AKT1 (0.49) MAPTNPC1RAB9ASMN1; SMN2POLB
SCHEMBL1780463 0.82 MAPT (0.43) MAPTNPC1RAB9ASMN1; SMN2NOX1
SCHEMBL10566349 0.81 NPC1 (0.40) NPC1RAB9ASMN1; SMN2CYP1A2POLB
SCHEMBL10565261 0.81 NOX1 (0.46) MAPTNPC1RAB9ASMN1; SMN2NOX1
SCHEMBL1781292 0.81 NPC1 (0.46) MAPTNPC1RAB9ASMN1; SMN2CTSL
SCHEMBL4083109 0.80 KDM4E (0.37) MAPTNPC1RAB9ACYP1A2CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405280-B2 Chromogenic substances and use thereof for the determination of carboxypeptidase activities DIAGNOSTICA STAGO (FR) 2008-07-29 US disclosed
US-7405280-B2 Chromogenic substances and use thereof for the determination of carboxypeptidase activities DIAGNOSTICA STAGO (FR) 2008-07-29 US disclosed
US-7405280-B2 Chromogenic substances and use thereof for the determination of carboxypeptidase activities DIAGNOSTICA STAGO (FR) 2008-07-29 US disclosed
US-20050107305-A1 Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities SOCIETE DIAGNOSTICA-STAGO (FR) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107305-A1 Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities CPA3, CPA4, CPA1 MAPT 4668/4885NPC1 2059/4885RAB9A 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.